Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opening Session Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




May
25
Today In Oncology
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo